← Leaderboards
Cloud Peter Paweletz
Dana-Farber Cancer Inst
$2,458,484
Attributed
$2,458,484
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $523.8K · FY2018–24$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,458,484 · 2
By mechanism
R01$2,233,486 · 1
R41$224,998 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Nathanael Schiander Gray$36,761,550
- Anthony G Letai$22,380,537
- David A Barbie$12,794,638
- Jean Zhao$18,430,855
- Lorenzo Trippa$1,815,428
Others in their field
Other Emerging Leaders on “Targeted Treatment”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,912,072
- Leonard Freedman · Leidos Biomedical Research, Inc.$66,755,704
- Susan Abushakra · Alzheon, Inc.$47,265,244
Research focus
Targeted TreatmentMutationMalignant NeoplasmsPlasmaTumorBlood TestsGenotypeLiquid BiopsyMutantNon-Small-Cell Lung CarcinomaDana-Farber Cancer InstituteTreatment ResponseCancer CareDiagnosticDrug TargetingEpidermal Growth Factor ReceptorBiological MarkersCaringMeasurementMonitorClinical TrialsDna AnalysisAdvanced Malignant NeoplasmComplement
Grant awards (6)
Early change in plasma tumor DNA as a patient and trial-level diagnostic in advanced lung cancer$326,540
R01 · FY2024 · CA · contact PI
Early change in plasma tumor DNA as a patient and trial-level diagnostic in advanced lung cancer$427,031
R01 · FY2023 · CA · contact PI
Early change in plasma tumor DNA as a patient and trial-level diagnostic in advanced lung cancer$435,266
R01 · FY2022 · CA · contact PI
Early change in plasma tumor DNA as a patient and trial-level diagnostic in advanced lung cancer$523,812
R01 · FY2021 · CA · contact PI
Early change in plasma tumor DNA as a patient and trial-level diagnostic in advanced lung cancer$520,837
R01 · FY2020 · CA · contact PI
Continuous emulsion digital PCR (cdPCR) for low-cost, rapid, near point-of-care genotyping of non-small cell lung cancer$224,998
R41 · FY2018 · CA · contact PI